Article Text

Download PDFPDF
Authors' response: the role of risedronate in osteopenia in Crohn's disease
  1. Ad A van Bodegraven1,
  2. Birgit I Witte2,
  3. Paul Lips3
  4. for the Crohn and Bone Study Group of the Dutch Initiative on Crohn and Colitis (ICC)
  1. 1 Department of Gastroenterology and Hepatology, VUmc, Amsterdam, The Netherlands
  2. 2 Department of Epidemiology and Biostatistics, VUmc, Amsterdam, The Netherlands
  3. 3 Endocrine Section, Department of Internal Medicine, VUmc, Amsterdam, The Netherlands
  1. Correspondence to Dr Ad A van Bodegraven, Department of Gastroenterology and Hepatology, VUmc, PO Box 7057, Amsterdam 1007 MB, The Netherlands; v.bodegraven{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the comments of Buchan and Manuel concerning our risedronate intervention trial in osteopenic patients with Crohn's disease.1 ,2

They stipulated that exclusion of patients with vitamin D deficiency limited the significance of the performed study, as this deficiency is frequently observed in Crohn's disease. It is however well known that replenishment of vitamin D (and calcium) in patients with vitamin D deficiency would lead to a rapid improvement of bone density, irrespective of any effect of risedronate. As assessment of a therapeutic effect of the latter was our primary study aim, we …

View Full Text


  • Correction notice The title of this letter has changed since published Online First.

  • Contributors AAvB, BIW and PL prepared the letter of response. All subsequent authors critically reviewed the letter and approved its contents.

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles